Stockscreener 앱 받기
41.81
7.44%
-3.36
시간 외 거래:
41.99
0.18
+0.43%
전일 마감가:
$45.17
열려 있는:
$45.99
하루 거래량:
2.81M
Relative Volume:
1.34
시가총액:
$2.87B
수익:
$18.09M
순이익/손실:
$-208.87M
주가수익비율:
-11.90
EPS:
-3.5125
순현금흐름:
$-178.15M
1주 성능:
-14.85%
1개월 성능:
+56.24%
6개월 성능:
+78.75%
1년 성능:
+192.79%
1일 변동 폭
$41.15
$46.09
1주일 범위
$41.15
$49.70
52주 변동 폭
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
명칭
Uniqure Nv
전화
1-339-970-7000
주소
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
41.81 | 3.17B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2026-03-09 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2026-03-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | 개시 | Wolfe Research | Peer Perform |
| 2026-01-28 | 개시 | Barclays | Equal Weight |
| 2025-11-04 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-04-01 | 재개 | Chardan Capital Markets | Buy |
| 2024-12-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-02-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-17 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-24 | 개시 | H.C. Wainwright | Buy |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-09 | 개시 | Jefferies | Buy |
| 2020-11-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-08-25 | 개시 | Raymond James | Strong Buy |
| 2020-07-31 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-06-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 개시 | Cowen | Outperform |
| 2019-12-03 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Outperform |
| 2019-10-11 | 개시 | Stifel | Buy |
| 2019-09-25 | 개시 | Bernstein | Outperform |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-07-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-07-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
모두보기
Uniqure Nv 주식(QURE)의 최신 뉴스
Precision Trading with Uniqure N.v. (QURE) Risk Zones - Stock Traders Daily
Price to earnings forward of uniQure N.V. – LSE:0EE0 - TradingView
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure - Stocktwits
Form 144 uniQure N.V. For: 30 June - Investing.com UK
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
uniQure (QURE) CMO auto-sells shares for RSU tax withholding, keeps stake - Stock Titan
Form 144 uniQure N.V. For: 30 June By Investing.com - Investing.com Canada
UniQure (NASDAQ: QURE) files Form 144 to sell 30,000 shares via Citigroup - Stock Titan
UniQure (NASDAQ: QURE) insider notice to sell 21,167 shares - Stock Titan
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Price to book forward of uniQure N.V. – SWB:UQ1 - TradingView
uniQure N.V. moves ahead with $225 million public offering. Capital raise reshapes the gene therapy - AD HOC NEWS
uniQure N.V. (QURE) Investors: Kessler Topaz Meltzer & Check, LLP - The National Law Review
QURE Maintained by HC Wainwright & Co. -- Price Target Raised to $80 - GuruFocus
Enterprise value to EBITDA forward of uniQure N.V. – SWB:UQ1 - TradingView
Enterprise value to revenue forward of uniQure N.V. – SWB:UQ1 - TradingView
Price to sales forward of uniQure N.V. – GETTEX:UQ1 - TradingView
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $80 - 富途牛牛
Bronstein, Gewirtz & Grossman, LLC Is Investigating uniQure N.V. (QURE) And Encourages Stockholders to Connect - The National Law Review
Price to earnings forward of uniQure N.V. – BMV:QURE/N - TradingView
UniQure surges on plans to seek US nod for gene therapy - MSN
uniQure N.V. Actuals & Estimates (BX:UQ1) - TradingView
Form 144 uniQure N.V. For: 26 June By Investing.com - Investing.com South Africa
Form 144 uniQure N.V. For: 26 June - Investing.com UK
uniQure NV | 4: Statement of changes in beneficial ownership of securities-Officer Kapusta Matthew C - Moomoo
uniQure (QURE) CEO Kapusta sells 35K shares after exercising options - Stock Titan
UniQure (QURE) files Rule 144 to sell 22,402 RSU shares; prior 45,000 sold - Stock Titan
Enterprise value to EBIT forward of uniQure N.V. – NASDAQ:QURE - TradingView
uniQure N.V. Actuals & Estimates (FWB:UQ1) - TradingView
QURE Maintained by Mizuho -- Price Target Raised to $68.00 - GuruFocus
Gene Therapy Co. Announces Initial Data for Refractory Epilepsy Treatment Gets Buy Rating - Streetwise Reports
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure N.V. Actuals & Estimates (LS:A1XDTV) - TradingView
uniQure (QURE) Is Up 6.1% After Equity Raise And FDA Backing For Accelerated HD FilingHas The Bull Case Changed? - simplywall.st
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure prices upsized $225M public offering of ordinary shares - MSN
Price to sales forward of uniQure N.V. – LSX:A1XDTV - TradingView
uniQure closes $259M public offering at $45.50 per share By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of uniQure N.V. – LSX:A1XDTV - TradingView
UniQure Closes $259 Million Stock Offering - marketscreener.com
uniQure closes $259M public offering at $45.50 per share - Investing.com
uniQure Closes $259 Million Public Offering of Ordinary Shares - Quiver Quantitative
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times
UniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - marketscreener.com
uniQure raises $259M as underwriters buy more shares - Stock Titan
uniQure NV | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Kapusta (QURE) sells 28,716 shares after option exercise on 06/25/2026 - Stock Titan
Price to earnings forward of uniQure N.V. – LSX:A1XDTV - TradingView
Price to book forward of uniQure N.V. – LSX:A1XDTV - TradingView
Enterprise value to EBITDA forward of uniQure N.V. – LSX:A1XDTV - TradingView
Uniqure Nv (QURE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Uniqure Nv 주식 (QURE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Sale |
46.42 |
30,000 |
1,392,600 |
148,235 |
| Kaye Jack | Director |
Jun 30 '26 |
Option Exercise |
23.44 |
21,167 |
496,230 |
43,056 |
| Kaye Jack | Director |
Jun 30 '26 |
Sale |
46.44 |
21,167 |
983,030 |
25,996 |
3.86%
자본화:
|
볼륨(24시간):